drugset / Trial / NCT06461026
L9LS MAb in Malian Infants
Phase 1
Active not recruiting
180 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Harvard School of Public Health (HSPH) · collabIndiana University · collabNational Institutes of Health (NIH) · collabUniversity of Washington · collab
RandomizedSequentialQuadruple-blindPrevention
Summary
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of L9LS in infants in Mali and to evaluate the impact of L9LS on subsequent R21/Matrix-MTM vaccine immunogenicity.
Timeline
- Start
- 2024-08-19
- Primary completion
- 2025-06-27
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L9LS | Monoclonal antibody | 150 mg | Intramuscular |